Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark Clemons

Showing results (111-120 of 267) with videos related to

Pageof 27
Sort By:
Journal of Pain Research|February 28, 2020
Applying Serum Cytokine Levels to Predict Pain Severity in Cancer PatientsJennifer Fazzari, Jesse Sidhu, Shreya Motkur, et al.
Breast Cancer Research and Treatment|January 7, 2016
Choice of study endpoint significantly impacts the results of breast cancer trials evaluating chemotherapy-induced nausea and vomitingTerry Ng, Sasha Mazzarello, Zhou Wang, et al.
The Journal of Supportive Oncology|October 20, 2007
Chemotherapy-induced nausea and vomiting in breast cancer patients: a prospective observational studyChristopher M Booth, Mark Clemons, George Dranitsaris, et al.
Journal of Cancer Policy|May 13, 2022
DECOLONIZING CANCER CARE IN CANADAMatthew Beckett, Katherine Cole, Mitchell White, et al.
Current Oncology (Toronto, Ont.)|March 12, 2016
De-escalation of bone-targeted agents for metastatic prostate cancerBrian Younho Hong, Mohammed F K Ibrahim, Ricardo Fernandes, et al.
Breast Cancer Research and Treatment|August 11, 2019
Randomized window of opportunity trial evaluating high-dose vitamin D in breast cancer patientsAngel Arnaout, Susan Robertson, Gregory R Pond, et al.
American Journal of Clinical Oncology|July 12, 2012
Randomized feasibility study of de-escalated (every 12 wk) versus standard (every 3 to 4 wk) intravenous pamidronate in women with low-risk bone metastases from breast cancerEitan Amir, Orit Freedman, Lindsay Carlsson, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|November 1, 2007
A randomised, placebo-controlled, double-blind trial of the effects of d-methylphenidate on fatigue and cognitive dysfunction in women undergoing adjuvant chemotherapy for breast cancerHelen G Mar Fan, Mark Clemons, Wei Xu, et al.
Current Oncology (Toronto, Ont.)|December 22, 2023
Shorter Durations of Anti-HER2 Therapy for Patients with Early-Stage, HER2-Positive Breast Cancer: The Physician PerspectiveMichelle Bradbury, Marie-France Savard, Lisa Vandermeer, et al.
Breast Cancer Research and Treatment|September 4, 2010
Phase II, double-blind, randomized trial of capecitabine plus enzastaurin versus capecitabine plus placebo in patients with metastatic or recurrent breast cancer after prior anthracycline and taxane therapyMark Clemons, Anil A Joy, Radhi Abdulnabi, et al.
Pageof 27

Showing results (111-120 of 267) with videos related to

Sort By:
Pageof 27
Journal of Pain Research|February 28, 2020
Applying Serum Cytokine Levels to Predict Pain Severity in Cancer PatientsJennifer Fazzari, Jesse Sidhu, Shreya Motkur, et al.
Breast Cancer Research and Treatment|January 7, 2016
Choice of study endpoint significantly impacts the results of breast cancer trials evaluating chemotherapy-induced nausea and vomitingTerry Ng, Sasha Mazzarello, Zhou Wang, et al.
The Journal of Supportive Oncology|October 20, 2007
Chemotherapy-induced nausea and vomiting in breast cancer patients: a prospective observational studyChristopher M Booth, Mark Clemons, George Dranitsaris, et al.
Journal of Cancer Policy|May 13, 2022
DECOLONIZING CANCER CARE IN CANADAMatthew Beckett, Katherine Cole, Mitchell White, et al.
Current Oncology (Toronto, Ont.)|March 12, 2016
De-escalation of bone-targeted agents for metastatic prostate cancerBrian Younho Hong, Mohammed F K Ibrahim, Ricardo Fernandes, et al.
Breast Cancer Research and Treatment|August 11, 2019
Randomized window of opportunity trial evaluating high-dose vitamin D in breast cancer patientsAngel Arnaout, Susan Robertson, Gregory R Pond, et al.
American Journal of Clinical Oncology|July 12, 2012
Randomized feasibility study of de-escalated (every 12 wk) versus standard (every 3 to 4 wk) intravenous pamidronate in women with low-risk bone metastases from breast cancerEitan Amir, Orit Freedman, Lindsay Carlsson, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|November 1, 2007
A randomised, placebo-controlled, double-blind trial of the effects of d-methylphenidate on fatigue and cognitive dysfunction in women undergoing adjuvant chemotherapy for breast cancerHelen G Mar Fan, Mark Clemons, Wei Xu, et al.
Current Oncology (Toronto, Ont.)|December 22, 2023
Shorter Durations of Anti-HER2 Therapy for Patients with Early-Stage, HER2-Positive Breast Cancer: The Physician PerspectiveMichelle Bradbury, Marie-France Savard, Lisa Vandermeer, et al.
Breast Cancer Research and Treatment|September 4, 2010
Phase II, double-blind, randomized trial of capecitabine plus enzastaurin versus capecitabine plus placebo in patients with metastatic or recurrent breast cancer after prior anthracycline and taxane therapyMark Clemons, Anil A Joy, Radhi Abdulnabi, et al.
Pageof 27